As the leader in identifying and validating human gene targets essential for viral replication, Zirus provides an extensive platform for the development of treatments to virtually any virus of commercial interest. Many of the company’s targets provide selective and effective inhibition against a particular family of viruses, while other targets can be used to inhibit several families of viruses that may cause a single disease.

Inhibiting Zirus targets with potential Zirus drugs blocks infection of all commercially important viruses tested to date in vitro. Zirus and its collaborators have identified specific gene targets and potential drugs for Flu, HIV/AIDS, pox viruses, Ebola, Marburg, RSV, herpes virus, common cold viruses, measles virus, and the polio virus. In addition, Zirus is actively discovering additional targets for many viruses including SARS and Hepatitis C Virus. The numbers of available Zirus targets makes selection of drugs for any of these diseases possible.

Zirus has identified specific gene targets and drugs for Flu, HIV/AIDS, pox viruses, Ebola, Marburg, RSV, herpes virus, common cold viruses, measles virus, and the polio virus and others.